NCT05348785: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
- State
- Completed
- Phase
- Phase 2
- People
- 650 taking part
- Started
- 19 Apr 2022
- Primary completion
- 9 Mar 2026
- Arms
- BIIB122 225 mg
- Results
- None posted
- 19 Apr 2022: Trial started
- 27 Apr 2022: Trial registered
- 9 Mar 2026: Trial completed